Header

UZH-Logo

Maintenance Infos

Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance


Schlagenhauf, Patricia; Steffen, Robert; Lobel, H; Johnson, R; Letz, R; Tschopp, Alois; Vranjes, Nenad; Bergqvist, Y; Ericsson, O; Hellgren, U; Rombo, L; Mannino, S; Handschin, J; Stürchler, D (1996). Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Tropical Medicine & International Health, 1(4):485-494.

Abstract

This longitudinal study of travellers to Africa taking mefloquine (MQ) chemoprophylaxis aimed to quantify and assess non-serious adverse events (AE) occurring during short-term prophylaxis and relate these to concentrations of racemic MQ, its enantiomers and metabolite. A total of 420 volunteers (52% F) participated. AEs with some impact on activities were reported by 11.2% of participants including 7.9% of neurological/psychiatric symptoms. Women were more likely to report AEs (P = 0.02). The standardized questionnaires used showed more pathological indicators in travellers who reported subjective AE with significantly more dizziness, distress, sleep disturbances and a high total mood disturbance (TMD) in the AE group. There was, however, no significant performance deficit in computerized psychomotor tests in those experiencing AE. Furthermore, no significant differences were observed in enantiomer ratios, metabolite concentrations, or racemic MQ levels in participants with or without AEs suggesting that these factors are not the main predictors of mefloquine intolerability.

Abstract

This longitudinal study of travellers to Africa taking mefloquine (MQ) chemoprophylaxis aimed to quantify and assess non-serious adverse events (AE) occurring during short-term prophylaxis and relate these to concentrations of racemic MQ, its enantiomers and metabolite. A total of 420 volunteers (52% F) participated. AEs with some impact on activities were reported by 11.2% of participants including 7.9% of neurological/psychiatric symptoms. Women were more likely to report AEs (P = 0.02). The standardized questionnaires used showed more pathological indicators in travellers who reported subjective AE with significantly more dizziness, distress, sleep disturbances and a high total mood disturbance (TMD) in the AE group. There was, however, no significant performance deficit in computerized psychomotor tests in those experiencing AE. Furthermore, no significant differences were observed in enantiomer ratios, metabolite concentrations, or racemic MQ levels in participants with or without AEs suggesting that these factors are not the main predictors of mefloquine intolerability.

Statistics

Citations

54 citations in Web of Science®
65 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:August 1996
Deposited On:21 May 2015 14:02
Last Modified:08 Dec 2017 13:05
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:1360-2276
Publisher DOI:https://doi.org/10.1046/j.1365-3156.1996.d01-85.x
PubMed ID:8765456

Download

Full text not available from this repository.
View at publisher